SQLite Web: event_store.db

Update row sig_7fd4a539b167 in signals

id

Primary key. TEXT

event_id

TEXT NOT NULL

watcher_id

TEXT

signal_type

TEXT NOT NULL

value

{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/714256/0001493152-26-017826.txt","as_of":"2026-04-18T03:05:05.644967+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/714256/0001493152-26-017826.txt","company":"Sanara MedTech Inc.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/714256/0001493152-26-017826.txt","article_chars":5000,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_48f7109e14cbeba7","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/714256/0001493152-26-017826.txt","content_type":"text/plain","enriched_at":"2026-04-18T03:41:54.208656+00:00","extraction_method":"trafilatura","fetched_description":"","fetched_title":"","final_url":"https://www.sec.gov/Archives/edgar/data/714256/0001493152-26-017826.txt","html_truncated":false,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/714256/0001493152-26-017826.txt","source_event_id":"evt_8d15769667f2","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"DEFA14A","fp":"d0e98389d813bba5","kind":"sec_filing","published_at":"20260417","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.86,"dates_mentioned":["2026-04-17","2026-04-17 (made available on or about)","2026-06-04"],"entities":[{"asset_class":"equity","name":"Sanara MedTech Inc.","relevance":"high","symbol":"","type":"issuer"},{"asset_class":"person","name":"Sara N. Ortwein","relevance":"high","symbol":"","type":"person"},{"asset_class":"person","name":"Rozell Mack III","relevance":"medium","symbol":"","type":"person"},{"asset_class":"person","name":"Ronald T. Nixon","relevance":"medium","symbol":"","type":"person"},{"asset_class":"regulator","name":"U.S. Securities and Exchange Commission","relevance":"medium","symbol":"","type":"regulator"}],"event_type":"listing","information_gaps":["What changed vs prior known state is only partially inferable: the supplement describes new/contingent leadership and compensation items, but the prior proxy statement\u2019s corresponding baseline details are not included in the provided text.","No explicit statement is provided about whether these changes were previously disclosed in the April 17, 2026 definitive proxy statement; the supplement says it supplements and amends, but does not enumerate prior versions.","No financial guidance or company financial implications beyond director compensation are provided in the provided text."],"key_facts":["Form DEFA14A is a supplement to the company\u2019s Schedule 14A proxy statement for the annual meeting of shareholders to be held on June 4, 2026.","The supplement states it supplements and amends the definitive proxy statement filed April 17, 2026.","The board determined (effective as of the annual meeting and contingent upon election) to appoint Sara N. Ortwein as lead independent director for a three-year term beginning on the annual meeting date.","The supplement states Ms. Ortwein will receive an annual cash payment of $40,000 (paid over four quarters annually) in addition to amounts under the existing director compensation policy.","The supplement states that contingent on election at the annual meeting, Rozell Mack III will become chair of the Compensation Committee effective as of the annual meeting, and Ms. Ortwein will remain a member of the Compensation Committee.","The supplement states that contingent on election at the annual meeting, the title for Ronald T. Nixon will change from \u201cExecutive Chairman\u201d to \u201cChairman.\u201d","The supplement states the proxy card included with the proxy statement remains valid and no new proxy card or voting instructions are required if already submitted."],"numeric_claims":[{"label":"Lead independent director annual cash payment","value":"$40,000"},{"label":"Lead independent director term length","value":"three-year term"},{"label":"Payment schedule","value":"paid over four quarters annually"},{"label":"Annual meeting date","value":"June 4, 2026"},{"label":"Definitive proxy statement filing date referenced","value":"April 17, 2026"}],"primary_claim":"The company\u2019s DEFA14A supplement appoints Sara N. Ortwein as lead independent director (effective at the annual meeting, contingent on election) and discloses related board leadership and compensation changes.","relevance_score":0.62,"sentiment":"neutral","source_quality":"high","summary":"Sanara MedTech Inc. filed a DEFA14A supplement to its Schedule 14A proxy statement for its June 4, 2026 annual meeting. The supplement discloses board leadership changes, including appointing Sara N. Ortwein as lead independent director and changing committee chair and executive chairman titles contingent on her/his election.","topics":["DEFA14A","Schedule 14A proxy supplement","annual meeting of shareholders","lead independent director","board leadership structure","director compensation","compensation committee chair","executive chairman title change"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form DEFA14A \u00b7 Sanara MedTech Inc. \u00b7 Filed 20260417","ticker":"SMTI","tickers":["SMTI"],"title":"SMTI filed DEFA14A","url":"https://www.sec.gov/Archives/edgar/data/714256/0001493152-26-017826.txt"}

TEXT NOT NULL

threshold

TEXT

direction

TEXT

severity

TEXT

window

TEXT

source

TEXT NOT NULL

reason_trace

TEXT

dedupe_key

TEXT NOT NULL

throttle_s

INTEGER (default 0

created_at

TEXT NOT NULL (default strftime('%Y-%m-%dT%H:%M:%fZ','now')

Cancel